BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
The most effective method to Decisively Use Open Record Rewards - 2Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- 3DEA seizes 1.7 million counterfeit fentanyl pills in Colorado storage unit
- 4Releasing Learning Experiences: A Survey of the \Learning Made Fun\ Instructive Application
- 55 Arising Vocations in Sustainable power
- Well known SUVs With Low Energy Utilization In 2024
- Nations for Youngsters to Visit
- Japan deploys the military to counter a surge in bear attacks
- Avoid Slam: Clearing the Street for the Eventual fate of Standard Size Trucks
- Help Your Efficiency: 10 Authoritative Apparatuses to Attempt
- Finding Ideal Date Spots for Two or three Encounters
- Get Cooking: 15 Speedy and Heavenly Recipes for Occupied Individuals
- 6 Monetary Arranging Administrations for Your Necessities
- Manual for Instructive Application for Youngsters
